Berlin, Germany, 6-23-2023
Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to common forms of chemotherapy. This discovery was made by a research team led by Martin Luther University Halle-Wittenberg (MLU) and Saarland University with the collaboration of CELLphenomics. For its new study, published in the scientific journal “Molecular Cancer”, the team analysed more than 140 tissue samples from bowel cancer patients from the IMI project OncoTrack, from which CELLphenomics emerged as a spin-off. The researchers found a link between the concentration of IGF2BP2 and the characteristics of the tumours. The findings could help to develop better diagnostic procedures and possibly novel therapies in the future.
